Cargando…
Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
Autores principales: | Vlaar, Alexander P J, de Bruin, Sanne, Brouwer, Matthijs C, van de Beek, Diederik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834467/ https://www.ncbi.nlm.nih.gov/pubmed/33521673 http://dx.doi.org/10.1016/S2665-9913(20)30424-0 |
Ejemplares similares
-
Efficacy matters: broadening complement inhibition in COVID-19
por: Mastellos, Dimitrios C, et al.
Publicado: (2021) -
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key
por: Lim, Endry H.T., et al.
Publicado: (2021) -
Inhibiting C5 in patients with severe COVID-19—the incorrect target?
por: Lim, Endry H T, et al.
Publicado: (2023) -
Complement activation in COVID-19 and targeted therapeutic options: A scoping review
por: Lim, Endry Hartono Taslim, et al.
Publicado: (2023) -
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
por: Lim, Endry H. T., et al.
Publicado: (2022)